The Europe Cervical Cancer Diagnostics and Therapeutics market has been estimated at USD 1043.76 Million in 2019 and is projected to reach USD 1233.68 Million by 2024, at a CAGR of 3.40% during the forecast period from 2019 - 2024.
Cervical cancers and cervical pre-cancers are classified by how they look under a microscope. The main types of cervical cancers are squamous cell carcinoma and adenocarcinoma. Cervical pre-cancers are diagnosed far more often than invasive cervical cancer.
The market for Europe Cervical Cancer Diagnostics and Therapeutics is mainly driven by the increase of pipeline cervical cancer screening tests and also due to effective government initiatives for both treatment and prevention of cancer.
But, due to the high treatment costs and uncertain reimbursement scenario, the market growth is hampered.
This research report segmented and sub-segmented into the following categories:
On the basis of diagnostics test, the Pap smear test segment dominated the market by Diagnostic test, holding a 45% share in the global market for cervical cancer diagnostic tests. The high growth rate of this segment can be attributed to the high efficiency of the test, low cost of the test in comparison with other tests available in the market, and rising awareness regarding a cancer diagnosis.
With high investment in R & D, a lot of companies are interested in setting up their units in this region, where they find a potential future.
Key players operating in the Europe Cervical Cancer Diagnostics and Therapeutics market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare and Volition Rx.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By diagnostics test
5.1.1 Pap smear test
5.1.2 HPV testing
5.1.3 Colposcopy
5.1.4 Cervical cancer biopsy
5.2 By methods
5.2.1 Molecular method
5.2.2 Cytopathological method
5.2.3 Physical method
5.3 By therapies
5.3.1 Surgery
5.3.2 Radiation therapy
5.3.3 Chemotherapy
5.3.4 Other therapies
5.4 By end-users
5.4.1 Hospitals
5.4.2 Laboratories
5.4.3 Independent physicians
5.4.4 Clinics
5.4.5 Other end-users
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Abbott Diagnostics
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Alere
9.3 Beckman Coulter
9.4 Clinical Genomics
9.5 Companion Dx
9.6 EDP Biotech
9.7 Epigenomics AG
9.8 Exact Sciences
9.9 Fujirebio
9.10 Genomic Tree
9.11 Metabiomics
9.12 Siemens Healthcare
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
